Skip to main content
. 2021 Apr 27;24(1):485. doi: 10.3892/mmr.2021.12124

Figure 3.

Figure 3.

NTS inhibits TLR-4, JAK2, STAT3 and IL-6 signaling. (A) Western blotting showing the expression of TLR-4, JAK2, p-JAK2, STAT3, p-STAT3 and IL-6 proteins following the treatment of C2C12 cells with 100 ng/ml LPS and 0.2 or 0.5 µg/ml NTS or 100 µM S3I-201 or 80 µM TLR4-C34 for 24 h. (B) Relative protein expression levels of TLR-4, JAK2, p-JAK2, STAT3, p-STAT3 and IL-6 were determined via densitometry and were normalized to β-actin. Data are representative of three independent experiments. (C) Relative expression levels of p-JAK2 and p-STAT3 were determined via densitometry and were normalized to total JAK2 and STAT3. (D) Flow cytometry (fluorescence-activated cell sorting) analysis of TLR-4 expression in C2C12 cells showing the expression levels of LPS-induced TLR-4 and its inhibition by 0.5 µg/ml NTS or 80 µM Toll-like receptor 4 inhibitor (TLR4-C34) for 24 h. *P<0.05, **P<0.01 and ***P<0.001 vs. control. NTS, non-toxic sulfur; TLR-4, Toll-like receptor 4; JAK2, Janus kinase 2; p-, phosphorylated; LPS, lipopolysaccharide; Con, control.